All In Biotech

Drug Trial Radar · NCT06195306

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

Phase 2 Study of Low Dose Tamoxifen +/- High Dose Omega-3 Fatty Acids in Overweight Postmenopausal Women at Increased Risk for Breast Cancer

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

Jul 28, 2025

Primary completion

Jan 1, 2027

Study completion Jan 1, 2028

Sponsor

Sponsor type
NIH
First posted
Jan 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 45 years, up to 74 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase II trial evaluates tamoxifen, with or without omega-3 fatty acids, for reducing risk of breast cancer among postmenopausal and overweight or obese women who are at increased risk of developing breast cancer. Tamoxifen is a selective estrogen receptor modulator. It works by blocking the effects of the hormone estrogen in the breast. Tamoxifen is approved by the Food and Drug Administration for prevention of breast cancer in women at increased risk. Omega-3 fatty acids have been shown to decrease the amount of fats made in the liver. Omega-3 fatty acids may work to prevent cancer in overweight or obese individuals. Tamoxifen with or without omega-3 fatty acids may be effective at reducing risk of breast cancer among women who are postmenopausal, overweight or obese, and at increased risk.

Conditions

  • Breast Atypical Hyperplasia
  • Breast Carcinoma
  • Breast Ductal Carcinoma In Situ
  • Breast Lobular Carcinoma In Situ

Interventions

  • Biospecimen CollectionProcedure

    Undergo collection of blood samples

  • MammographyProcedure

    Undergo mammography

  • Omega-3-Acid Ethyl EstersDrug

    Given PO

  • Questionnaire AdministrationOther

    Ancillary studies

  • Random Periareolar Fine-Needle AspirationProcedure

    Undergo RPFNA

  • TamoxifenDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in serum adiponectinTime frame: From baseline up to end of treatment (6 months)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of Kansas Cancer Center

    Kansas City, Kansas · Recruiting

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan · Recruiting

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.